MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months

DRUG2 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

B-cell LymphomaCutaneous T-cell LymphomaMycosis FungoidesSezary Syndrome

Phase 2

Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001)

CompletedNCT00091559

Merck Sharp & Dohme LLCCutaneous T-cell Lymphoma, Mycosis Fungoides, Sezary Syndrome

Start: 2005-02-03End: 2006-03-13Updated: 2017-04-05

An Investigational Drug Study With Suberoylanilide Hydroxamic Acid in Relapsed Diffuse Large B-cell Lymphoma (0683-013)

CompletedNCT00097929

Merck Sharp & Dohme LLCB-cell Lymphoma

Start: 2005-05-01End: 2006-07-31Updated: 2017-04-07

Related Papers

Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma.

2008-02-21146 citations

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.

2007-06-18728 citations